Collectively, these findings suggest that higher expression of immune checkpoint molecules, such as CTLA-4 and PD-L1, is linked to a poorer prognosis in BCP-ALL, highlighting a distinct immune cell context in the BCP-ALL BM compared to healthy controls, even in monocytes and macrophages. Here, CTLA4 is linked to acute lymphoblastic leukemia.